KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Current Liabilities (2017 - 2026)

Aquestive Therapeutics has reported Total Current Liabilities over the past 9 years, most recently at $47.6 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 152.36% year-over-year to $47.6 million; the TTM value through Dec 2025 reached $47.6 million, up 152.36%, while the annual FY2025 figure was $47.6 million, 152.36% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $47.6 million at Aquestive Therapeutics, up from $25.6 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $47.6 million in Q4 2025 and troughed at $13.9 million in Q2 2024.
  • A 5-year average of $26.1 million and a median of $23.6 million in 2023 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: tumbled 64.05% in 2024 and later skyrocketed 152.36% in 2025.
  • Year by year, Total Current Liabilities stood at $22.0 million in 2021, then soared by 79.97% to $39.5 million in 2022, then tumbled by 53.68% to $18.3 million in 2023, then grew by 3.04% to $18.9 million in 2024, then skyrocketed by 152.36% to $47.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for AQST at $47.6 million in Q4 2025, $25.6 million in Q3 2025, and $23.2 million in Q2 2025.